EADO-WCM 2021 - 10th World Congress of Melanoma and 17th EADO Congress (Virtual Meeting)
Apr 15 - Apr 17, 2021 | RomeItaly
LARVOL is not affiliated with 10th World Congress of Melanoma and 17th EADO Congress (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 22 abstracts linked to Trials
[VIRTUAL] Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
[VIRTUAL] Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data
[VIRTUAL] KEYNOTE 629: Phase 2 study of pembrolizumab monotherapy for locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma
[VIRTUAL] Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or are intolerant to hedgehog inhibitors
[VIRTUAL] Primary analysis of Phase 2 results for cemiplimab in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors
[VIRTUAL] Analysis of efficacy outcomes using ERIVANCE-like methodology in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
[VIRTUAL] Two patients treated with Hedgehog inhibitor (HHI) and anti-PD-1 antibody for concomitant diagnosis of advanced Basal Cell Carcinoma (aBCC) and cutaneous Squamous Cell Carcinoma (cSCC)
[VIRTUAL] A Phase II study of intralesional Daromun (L19IL2 + L19TNF) in non-melanoma skin cancer patients with localized disease (NCT04362722)
[VIRTUAL] Phase II trial evaluating Resminostat for maintenance treatment of patients with advanced stage (Stage IIB‑IVB) mycosis fungoides (MF) or Sézary syndrome (SS) – RESMAIN study
[VIRTUAL] Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600mutated melanoma: first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study
[VIRTUAL] PIVOT-12: a Phase 3 randomized study of adjuvant bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) versus NIVO in completely resected cutaneous melanoma at high risk for recurrence
[VIRTUAL] KEYMAKER-U02: Phase 1/2 study of investigational agents with or without pembrolizumab or pembrolizumab alone in patients with melanoma
[VIRTUAL] First-line CMP-001 plus nivolumab vs nivolumab alone in a randomized, open-label, phase 2/3 study (CMP-001-011) in patients with unresectable or metastatic melanoma
[VIRTUAL] Nemvaleukin alfa monotherapy in patients with advanced melanoma: ARTISTRY-1
[VIRTUAL] Phase I trial: personalized vaccination with IKKb-matured, RNA-loaded dendritic cells for metastatic uveal melanoma